To align with fundamental criteria for screening, the causal relationship of Lp(a) and ASCVD risk requires confirmation from cardiovascular outcome trials of highly effective Lp(a)-lowering agents, with demonstration of cost-effectiveness (3, 5). This evidence concerns the gene LPA and atherosclerosis.